Portfolio of Immune Checkpoint Inhibitor Stocks
Here are 4 companies that offer immune checkpoint inhibitor cancer treatments:
- AstraZeneca (AZN) - durvalumab Imfinzi
- Bristol-Myers Squibb (BMY) - nivolumab Opdivo and ipilimumab Yervoy
- Merck (MRK) - pembrolizumab Keytruda
- Roche Holding (RHHBY) - atezolizumab TECENTRIQ
| 4 Checkpoint Inhibitor Stocks | ||
|---|---|---|
Stock Returns & Price Chart | Symbol | Recent Prices & |
| AstraZeneca | AZN | |
| Bristol-Myers Squibb | BMY | |
| Merck | MRK | |
| Roche Holding AG | RHHBY | |
| Price data from Quandl as of most recent close. | ||
To inspect the performance of the Checkpoint Inhibitor Stocks
portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.
The current value of a $10,000 investment is $35,740. The percent return is 257.40%. The annualized return is 13.58%.
| Return Summary for Checkpoint Inhibitor Stocks | |
|---|---|
| Start Date | May-29-2009 |
| Start Investment | $10,000.00 |
| End Date | May-24-2019 |
| Current Value of Investment | $35,740.27 |
| Total Return | 257.40% |
| Annualized Return | 13.58% |
| Min Date | May-29-2009 |
| Min Price | $10,000.00 |
| Max Date | Feb-28-2019 |
| Max Price | $37,394.20 |
| # Values | 121 |
| Number Returns | 7,260 |
| Number Profitable Returns | 6,875 |
| Percent Profitable Returns | 94.70% |
| Number Unprofitable Returns | 385 |
| Percent Unprofitable Returns | 5.30% |
| Profitable to Unprofitable Returns Ratio | 17.86 |
NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.
Related Portfolios
Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks